These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7897240)

  • 1. Prevention of acute graft-versus-host disease by treatment with a novel immunosuppressant. Cholera toxin B subunit.
    Yankelevich B; Brown E; Mazumder A
    J Immunol; 1995 Apr; 154(7):3611-7. PubMed ID: 7897240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease.
    Via CS; Rus V; Gately MK; Finkelman FD
    J Immunol; 1994 Nov; 153(9):4040-7. PubMed ID: 7930611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B.
    Tao HR
    Hokkaido Igaku Zasshi; 1998 May; 73(3):227-37. PubMed ID: 9719949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
    Georgantas RW; Bohana-Kashtan O; Civin CI
    Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease.
    Badillo AT; Peranteau WH; Heaton TE; Quinn C; Flake AW
    Br J Haematol; 2008 Apr; 141(2):224-34. PubMed ID: 18318768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR; Taylor PA; Vallera DA
    J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
    Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
    J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin.
    Epstein J; Bealmear PM; Kennedy DW; Herrmann MJ; Islam A; Wiedl SC
    Exp Hematol; 1986 Oct; 14(9):845-9. PubMed ID: 2944759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
    Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.